ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target. Cancer ...
Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral ...
CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling earlier, more ...
WO 2026/178627 covers methods, uses and compositions pairing Streptococcus salivarius SALI-10 with sorbitol, creating a ...
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient ou ...
Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation will be featured at the upcoming ...
FDA clearance of its Investigational New Drug (IND) application for MC001, the Company's first-in-class dimeric ...
Dr. Meltzer joins Avilar as the company advances its lead ATAC program toward the clinic. The program is an ATAC designed to ...
The incidence of melanoma is steadily rising, with annual cases projected to increase by more than 50% between 2020 and 2040.
UPPSALA, SE / ACCESS Newswire / October 5, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - "We reaffirm our target of reaching ...
Privo Technologies today announced results from the CLN-004 Phase 2 (Cohort 1) trial evaluating PRV111, a nanoengineered, ...
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is proud to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results